Effect of amlodipine on insulin secretion, glucose, lipid profile and urinary albumin excretion in patients with mild hypertension and non-insulin-dependent diabetes

Clinical Drug Investigation

Volumn 13, Issue SUPPL. 1, 1997, Pages 56-66

  Faglia, E ^a   Favales, F ^a   Quarantiello, A ^a   Nosari, I ^b   Cortinovis, F ^b   Girelli, A ^c   Rocca, L ^c   Moratti, F ^d   Braga, A ^d   Mariani, G ^e   Previato, M ^e   Testori, G ^f   Villani, P ^f   Rocca, A ^g   Musacchio, N ^g   Paleari, F ^h   Ghezzi, A ^h  

^a OSPEDALE NIGUARDA CA GRANDA   (Italy)

^b OSPEDALI RIUNITI   (Italy)

^c Ospedale Civile   (Italy)

^d Ospedale Civile   (Italy)

^e SAN CARLO BORROMEO HOSPITAL   (Italy)

^f FATEBENEFRATELLI HOSPITAL   (Italy)

^g Ospedale Bassini   (Italy)

^h SAN GERARDO HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; AMLODIPINE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; LIPID; LIPOPROTEIN A;

ADULT; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BORDERLINE HYPERTENSION; CLINICAL FEATURE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DRUG EFFICACY; EYE DISEASE; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HEART DISEASE; HEART PROTECTION; HEART RATE; HUMAN; INSULIN RELEASE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLISM; MICROALBUMINURIA; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEINURIA; SIDE EFFECT; URINARY EXCRETION;

EID: 0030751702     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-199700131-00011     Document Type: Article

References (53)

1. Fuller JH. Epidemiology of hypertension associated with diabetes mellitus. Hypertension 1985; 7 Suppl. 2: 3-7
2. Fuller JH, Head J, WHO Multinational Study Group. Blood pressure, proteinuria and their relationship with circulatory mortality: the WHO multinational study of vascular disease in diabetics. Diabetes Metab 1989; 15: 273-7
3. Selby JV, Fitzsimmons SC, Newman JM, et al. The natural history and epidemiology of diabetic nephropathy. JAMA 1990; 263: 1954-60
4. Klein R, Klein BEK, Moss SE, et al. Is blood pressure a predictor of the incidence or progression of diabetic retinopathy? Arch Intern Med 1989; 149: 2427-32
5. Weidmann P, Boehlen LM, de Courten M. Pathogenesis and treatment of hypertension associated with diabetes mellitus. Am Heart J 1993; 125: 1498-513
6. Epstein M, Sowers JR. Diabetes mellitus and hypertension. Hypertension 1992; 19: 403-18
7. Dzau VJ. Treatment strategies: an evaluation of antihypertensive therapy. Am J Med 1989; 86 Suppl. 1B: 113-5
8. Houston MC. Treatment of hypertension in diabetes mellitus. Am Heart J 1989; 118: 819-29
9. Trost BN, Weidmann P. Metabolic effects of calcium antagonists in humans, with emphasis on carbohydrate, lipid, potassium and uric acid homeostases. J Cardiovasc Pharmacol 1988; 12 Suppl. 6: S86-92
10. Ferrari P, Rosman J, Weidmann P. Antihypertensive agents, serum lipoproteins and glucose metabolism. Am J Cardiol 1991; 67: 26-35B
11. Chellingsworth MC, Kendall MJ, Wright AD, et al. The effects of verapamil, diltiazem, nifedipine and propranolol on metabolic control in hypertensive non-insulin dependent diabetes mellitus. J Hum Hypertens 1989; 3: 35-9
12. Busch Sorensen M, Sjostrand H, Sengelov H, et al. Influence of short term verapamil treatment on glucose metabolism in patients with non-insulin dependent diabetes mellitus. Eur J Clin Pharmacol 1991; 41: 401-4
13. Bhatnagar SK, Amin MAA, Al-Yusuf AR. Diabetogenic effects of nifedipine. Br Med J 1984; 289: 19-23
14. Abadie E, Gauville C, Brisson C. Nifedipine and endocrine status in diabetic patients. Br J Clin Pharmacol 1984; 18: 648-50
15. Shamoon H, Baylor P, Kambosos D, et al. Influence of oral verapamil on glucoregulatory hormones in man. J Clin Endocrinol Metab 1985; 60: 536-41
16. Ferrier C, Ferrari P, Weidmann P, et al. Antihypertensive therapy with the calcium channel blocker verapamil and/or the angiotensin converting enzyme inhibitor enalapril in diabetic patients. Diabetes Care 1991; 14: 911-4
17. Kaplan NM, Rosenstock J, Raskin P. A differing view of treatment of hypertension in patients with diabetes mellitus. Arch Intern Med 1987; 147: 1160-27
18. Brouhard BH. Antihypertensive therapy for patients with diabetes mellitus. Diabetes Care 1992; 15: 918-21
19. Charles S, Ketelsiegers JM, Buysschaert M, et al. Hyperglycaemic effect of nicardipine. Br Med J 1981; 283: 19-20
20. De Marinis L, Barbarino A. Calcium antagonists and hormone release. I. Effects of verapamil on insulin release in normal subjects and patients with islet cell tumor. Metabolism 1980; 29: 599-604
21. Giugliano D, Gentile S, Versa M, et al. Modulation by verapamil of insulin and glucagon secretion in men. Acta Diabetol Lat 1981; 18: 163-71
22. Futh MMT, Shieh SM, Wu DA, et al. Abnormalities of carbohydrate and lipid metabolism in patients with hypertension. Intern Med 1987; 147: 1035-8
23. Curb JD, Labarthe DR, Cooper SP, et al. Training and certification of BP observers. Hypertension 1983; 5: 610-4
24. Dischinger P, DuChene AG. Quality control aspects of blood pressure measurements in the Multiple Risk Factor Intervention Trial. Cont Clin Trials 1986; 7 Suppl.: 137-57S
25. Gjessing HJ, Matzen LE, Faber OK, et al. Fasting plasma C-peptide, glucagon stimulated plasma peptide, and urinary C-peptide in relation to clinical type of diabetes. Diabetologia 1989; 32: 305-11
26. Faber OK, Binder C. C-peptide response to glucagon. A test for the residual beta-cell function in diabetes mellitus. Diabetes 1977; 26: 605-9
27. Stamler J. Epidemiology, established major risk factors, and the primary prevention of coronary heart disease. In: Parmley W, Chatterjee K, editors. Cardiology. Philadelphia: Lippincott, 1987: 1-41
28. 1989 Guidelines for the management of mild hypertension: memorandum from a WHO/ISM Meeting. J Hypertens 1989; 7: 689-93
29. Joint National Committee. The fifth report of the Joint National Committee on the Detection, Evaluation and Treatment of High Blood Pressure. Arch Intern Med 1993; 153: 154-83
30. Pollare T, Lithell H, Morlin C, et al. Metabolic effects of diltiazem and atenolol: results from a randomised, double-blind study with parallel groups. Hypertension 1989; 7: 551-9
31. Pollare T, Lithell H, Berne C. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med 1989; 321: 868-73
32. Ramsay LE, Jackson Y. Diabetes, impaired glucose tolerance and insulin resistance with diuretics. Eur Heart J 1992; Suppl. 13: 68-71
33. Warram JH, Laffel LM, Valsania P, et al. Excess mortality associated with diuretic therapy in diabetes mellitus. Arch Intern Med 1991; 151 (7): 1350-6
34. Parving HH. Arterial hypertension in diabetes mellitus. In: Alberti KGMM, Defronzo RA, Keen H, et al., editors. International textbook of diabetes mellitus. Vol. II. Chichester; G Wiley and Sons, 1992: 1530-31
35. Trost B, Weidmann P. Effects of calcium antagonists on glucose homeostasis and serum lipids in non-diabetic and diabetic subjects: a review. J Hypertens 1987; 5 Suppl. 4: S81-104
36. Roth A, Miller H, Belhassenm B, et al. Slow-release verapamil and hyperglycemic metabolic acidosis. Ann Intern Med 1989; 110: 171-2
37. Berne C, Pollare T, Lithell H. Effects of antihypertensive treatment on insulin sensivity with special reference to ACE inhibitors. Diabetes Care 1991; 14 Suppl. 4: 39-47
38. Melbourne Diabetic Neuropathy Study Group. Comparison between perindropil and nifedipine in hypertensive and normotensive diabetic patients with microalbuminuria. BMJ 1991; 302: 210-6
39. Mimran A, Insua A, Ribstein J, et al. Comparative effect of captopril and nifedipine in normotensive patients with incipient diabetic nephropathy. Diabetes Care 1988; 11: 850-3
40. Bjorck S, Nyberg G, Mulec H, et al. Beneficial effects of angiotensin converting enzyme inhibition on renal function in patients with diabetic nephropathy. Br Med J 1986; 293: 471-4
41. DeMarie B, Bakris GL. Effects of different classes of calcium antagonists on proteinuria in diabetic subjects. Ann Intern Med 1990; 113: 987-8
42. Stornello M, Valvo EV, Scapellato L. Haemodynamic, renal and humoral effects of the calcium entry blocker nicardipine and converting enzyme inhibitor captopril in hypertensive type II diabetic patients with nephropathy. J Cardiovasc Pharmacol 1989; 14: 851-5
43. Baba T, Murabayashi S, Takebe K. Comparison of the renal effects of angiotensin converting enzyme inhibitor and calcium antagonist in hypertensive type 2 (non insulin-dependent) diabetic patients with microalbuminuria: a randomised controlled trial. Diabetologia 1989; 32: 40-4
44. Bakris GL. Effects of diltiazem or lisinopril on massive proteinuria associated with diabetes mellitus. Ann Intern Med 1990; 112: 707-8
45. Valentino VA, Wilson MD, Weart W, et al. A perspective on converting enzyme inhibitors and calcium channel antagonists in diabetic renal disease. Arch Intern Med 1991; 151: 2367-72
46. Weber MA. The evolution of antihypertensive therapy: current theoretical conditions and individualised treatment options. Am J Med 1992; 93 Suppl. 2A: 1-3S
47. Epstein M. Calcium antagonists and diabetic nephropathy. Arch Intern Med 1991; 151: 2361-4
48. Rosanssy SJ, Hoover DR, King L, et al. The association of blood pressure levels and change in renal function in hypertensive subjects. Arch Intern Med 1990; 150: 2073-6
49. Anderson S, Rennke HG, Garcia DL, et al. Short and long term effects of antihypertensive therapy in the diabetic rat. Kidney Int 1989; 36 (4): 526-36
50. Viberti GC, Wiseman MJ, Redmond S. Microalbuminuria: its history and potential for prevention of clinical nephropathy in diabetes mellitus. Diabetic Nephrop 1984; 3: 70-82
51. Mogensen CE. Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy. BMJ 1982; 285: 685-8
52. Parving HH, Hommel E. High blood pressure is a major factor in progression of diabetic nephropathy. J Diabetes Complications 1988; 2: 92-5
53. Parving HH, Andersen AR, Smidt UM, et al. Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet 1983; 1: 1175-9